Jeff Black

Jeff Black joined Applied Proteomics Inc., in September 2015, with nearly 25 years of experience in financial, operations management and advisory roles, including senior-level finance roles for six publicly-traded companies. Jeff joins API from AltheaDx, Inc., a molecular diagnostics company specializing in pharmacogenetic testing where he served as Chief Financial Officer. Jeff was a key member of the management team that grew the company from new product launch to $15 million in revenue in its first full year of commercialization. Prior to joining AltheaDx, Mr. Black served as Chief Financial Officer of Verenium Corporation, a Nasdaq-listed pioneer in the development and commercialization of high-performance enzymes for use in industrial processes. During his nine-year tenure at Verenium, Mr. Black played a leadership role in nearly $500 million of strategic, equity, and debt financing transactions, culminating in the sale of the company to BASF in 2013. Mr. Black’s prior experience includes serving as Executive Director of Accounting and Corporate Controller of Isis Pharmaceuticals, Inc., and principal and interim Financial Executive of Regent Pacific Management Corporation, a financial advisory firm through which he served as Vice President of Finance and Corporate Controller of Clarent Corporation and Vice President and Corporate Controller of Accelerated Networks, Inc. Mr. Black is a certified public accountant (inactive) and began his career with Ernst & Young LLP. Mr. Black currently serves on the board of directors of Cellana, Inc., a privately-held algae bioproducts company.